Evidence map›Paper›PMID 41605573›Full record

Observational studyBMJ open respiratory research2026

Prospective study of fibrosis in the lung endpoints (PROFILE): characteristics of an incident cohort of patients with idiopathic pulmonary fibrosis.

Toby M Maher, Gisli R Jenkins, Gauri Saini, Rebecca Braybrooke, Simon R Johnson, Felix Chua, Pauline T Lukey, Juliet K Simpson, Richard J Allen, Louise V Wain and 3 more

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Toby M Maher *USC Keck School of Medicine, Los Angeles, California, USA.
Gisli R Jenkins *Margaret Turner Warwick Centre for Fibrosing Lung Disease, Imperial College London National Heart and Lung Institute, London, England, UK.ORCID http://orcid.org/0000-0002-7929-2119
Gauri SainiRoyal Papworth Hospital, Cambridge, England, UK.
Rebecca BraybrookeRespiratory Medicine, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, University of Nottingham, Nottingham, England, UK.
Simon R JohnsonCentre for Respiratory Research and NIHR Biomedical Research Centre, School of Medicine, University of Nottingham, Nottingham, England, UK.ORCID http://orcid.org/0000-0002-9837-2763
Felix ChuaRoyal Brompton Hospital, London, London, UK.
Pauline T LukeyTarget to Treatment Consulting Ltd, Stevenage Bioscience Catalyst, Stevenage, UK.
Juliet K SimpsonGlaxoSmithKline Research & Development Limited, London, England, UK.
Richard J AllenNIHR Leicester Biomedical Research Centre, Leicester, England, UK.
Louise V WainNIHR Leicester Biomedical Research Centre, Leicester, England, UK.ORCID http://orcid.org/0000-0003-4951-1867
William A FahyGlaxoSmithKline Research & Development Limited, London, England, UK.
Philip L MolyneauxMargaret Turner Warwick Centre for Fibrosing Lung Disease, Imperial College London National Heart and Lung Institute, London, England, UK.ORCID http://orcid.org/0000-0003-1301-8800
Iain StewartMargaret Turner Warwick Centre for Fibrosing Lung Disease, Imperial College London National Heart and Lung Institute, London, England, UK iain.stewart@imperial.ac.uk.ORCID http://orcid.org/0000-0002-1340-2688

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIdiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease. Prospective study of fibrosis in the lung endpoints (PROFILE) was a prospective, observational cohort study designed to better define the natural history of IPF, understand disease biology and identify biomarkers to support disease management and enhance clinical trial design.

methodsIndividuals with an incident diagnosis of IPF were recruited between 2010 and 2017 across two co-ordinating centres in the UK. Demographics, clinical measurements and blood samples were obtained at baseline, and 1, 3, 6, 12, 24 and 36 months. Disease progression events were defined as death or relative forced vital capacity (FVC) decline >10% at 12 months. Survival estimates were modelled using Cox proportional hazards; longitudinal lung function decline was estimated using mixed effect models, specified with restricted cubic splines, a random intercept for participant and random effect for study visit. All models were adjusted for baseline age, sex and continuous baseline percent predicted FVC (ppFVC).

resultsA total of 632 participants were recruited, 77.1% were male, and mean age at enrolment was 70.4 years (SD 8.4). Mean baseline ppFVC was 79.5% (SD 19.2), and mean percent predicted DL

conclusionThe PROFILE cohort confirms that untreated IPF is inexorably progressive and inevitably fatal with a poor median survival from diagnosis.

Indexed as

Idiopathic Pulmonary FibrosisLungAgedBiomarkersDisease ProgressionFemaleHumansIncidenceMaleMiddle AgedProspective StudiesUnited KingdomVital CapacityBiomarkersIdiopathic Pulmonary Fibrosis

Identifiers

PMID41605573
PMCPMC12853555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.